Conclusions

Science and neuroscience are making landmark discoveries at a rate unknown in our lifetime or across history.  A relentless parade of new scientific developments is unfolding on many fronts.  The pace of advance is accelerating, and many rapidly-evolving, potentially transformative technologies are appearing on the horizon. 

 

Sensing nascent technologies and recognizing their potential has become a crucial priority for management.  Success in today’s world requires bold, decisive action based on keen insights into emerging revolutionary trends.  Forward-thinking leaders can be on the winning side of change by becoming early adopters and innovators who turn potential into opportunity.

To date, the pharmaceutical industry has focused on drug discovery for a cure, spending over $3.5 billion in Alzheimer’s R&D in the last 4 years with a 99.6% failure rate.  Our approach targets symptomatic relief, which is much simpler than a cure.  Results are achieved by optimizing neuron performance to enhance cognition using CRISPR.

 

Cognigenics’ innovative technology can improve  quality of life for millions of Alzheimer’s patients and their families, while lowering society’s overall cost for elder care.  Our innovative treatment method is protected by multiple patents pending and holds the promise of significant rewards in a rapid development timeframe.

Cognigenics, LLC

1390 N. McDowell Blvd., Suite G317

Petaluma, California 94954   USA

Voice: 1-772-324-8800

Email: office@cognigenics.co

Subscribe to our newsletter

© 2020 Cognigenics, LLC  All rights reserved.